Abstract
Background and Aims: Fibroblast growth factor 21 (FGF21) is considered a promising therapeutic agent for obesity and T2D. However, its role in NASH remains elusive. Therefore, we aimed to investigate the effects of hepatic FGF21 overexpression on NASH development in APOE*3-Leiden.CETP mice, a well-established model mimicking NASH initiation and progression in humans.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
